What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms

Brachytherapy

Volumn 1, Issue 2, 2002, Pages 83-89

  Stock, Richard G ^a   Stone, Nelson N ^a   Dahlal, Mehud ^a   Lo, Yeh Chi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dose; Prostate brachytherapy; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE;

ARTICLE; BLADDER EMPTYING; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HISTOGRAM; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION RESPONSE; RADIOISOTOPE THERAPY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY TRACT FUNCTION; URINE FLOW RATE; BIOPSY; BLOOD; BRACHYTHERAPY; MICTURITION DISORDER; PROSTATE TUMOR; TIME;

BIOPSY; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TIME FACTORS; URINATION DISORDERS;

EID: 0142227730     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1538-4721(02)00017-X     Document Type: Article

References (35)

1. Gelblum D.Y., Potters L., Ashley R.et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 45:1999;59-67.
2. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.
3. Stock R.G., Stone N.N., Wesson M.F.et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 32:1995;219-225.
4. Stone N.N., Ramin S.A., Wesson M.F.et al. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol. 153:1995;1555-1560.
5. Stock R.G., Stone N.N., Lo Y.C.et al. Post implant dosimetry for I-125 prostate implants. Definitions and factors affecting outcome Int J Radiat Oncol Biol Phys. 48:2000;899-906.
6. Stone N.N., Stock R.G., DeWyngaert J.K.et al. Prostate brachytherapy. Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three- dimensional dosimetry Radiat Oncol Invest. 3:1995;185-195.
7. Stock R.G., Stone N.N., Tabert A.et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
8. Nag S., Bice W., DeWyngaert K.et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 46:2000;221-230.
9. Yu Y., Anderson L.L., Li Z.et al. Permanent prostate seed implant brachytherapy. Report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys. 26:1999;2054-2076.
10. Barry M.J., Fowler F.J. Jr., O'Leary M.P.et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
11. Dixon W.J. BMDP statistical software manual. Release 7. 1992;University of California Press, Berkeley. p. 162.
12. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
13. Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
14. Cox D.R., Oakes D. Analysis of survival data. 1984;Chapman and Hall, London.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
16. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
17. Boersma L.J., van den Brink M., Bruce A.M.et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 41:1998;83-92.
18. Hanks G.E., Schultheiss T.E., Hanlon A.L.et al. Optimization of conformal radiation treatment of prostate cancer. Report of a dose escalation study Int J Radiat Oncol Biol Phys. 37:1997;543-550.
19. Zelefsky M.J., Cowen D., Fuks Z.et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate cancer. Cancer. 85:1999;2460-2468.
20. Hartford A.C., Niemierko A., Adams J.A.et al. Conformal irradiation of the prostate. Estimating long-term rectal bleeding risk using dose-volume histograms Int J Radiat Oncol Biol Phys. 36:1996;721-730.
21. Skwarchuk M.W., Jackson A., Zelefsky M.J.et al. Late rectal toxicity after conformal radiotherapy of prostate cancer. Multivariate analysis and dose-response Int J Radiat Oncol Biol Phys. 47:2000;103-113.
22. Fiveash J.B., Hanks G., Roach M.et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer. A multi-institutional review Int J Radiat Oncol Biol Phys. 47:2000;335-342.
23. Pollack A., Zagars G.K., Smith L.G.et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 18:2000;3904-3911.
24. Roach M., Meehan S., Kroll S.et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 156:1996;1719-1723.
25. Zelefsky M.J., Leibel S.A., Gaudin P.B.et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-497.
26. Stock R.G., Stone N.N., DeWyngaert J.K.et al. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer. 77:1996;2386-2392.
27. Stone N.N., Ratnow E.R., Stock R.G. Prior transurethral resection does not increase morbidity following real-time ultrasound guided prostate seed implantation. Tech Urol. 6:2000;123-127.
28. Desai J.D., Stock R.G., Stone N.N.et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
29. Lee W.R., McQuellon R.P., Harris-Henderson K.et al. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 46:2000;77-81.
30. Merrick G.S., Butler W.M., Lief J.H.et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;121-128.
31. Crook J., Robertson S., Collin G.et al. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 27:1993;31-37.
32. Dugan T.C., Shipley W.U., Young R.H.et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate. Correlation with original histological grade and current prostate specific antigen levels J Urol. 146:1991;1313-1316.
33. Kuban D.A., El-Mahdi A.M., Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 24:1992;409-414.
34. Prestidge B.R., Kaplan I., Cox R.S.et al. The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int J Radiat Oncol Biol Phys. 24:1992;403-408.
35. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.